表纸
市场调查报告书

全球生物相似药市场分析与预测:各产品、应用领域(肿瘤、生长激素、血液疾病、慢性疾病、自体免疫疾病)、地区 2018年~2025年

Biosimilars Market Size, Share & Trends Analysis Report By Product, By Application (Oncology, Growth Hormone, Blood Disorders, Chronic & Autoimmune Disorders), By Region, And Segment Forecasts, 2018 - 2025

出版商 Grand View Research, Inc. 商品编码 544803
出版日期 内容资讯 英文 70 Pages
商品交期: 2-3个工作天内
价格
Back to Top
全球生物相似药市场分析与预测:各产品、应用领域(肿瘤、生长激素、血液疾病、慢性疾病、自体免疫疾病)、地区 2018年~2025年 Biosimilars Market Size, Share & Trends Analysis Report By Product, By Application (Oncology, Growth Hormone, Blood Disorders, Chronic & Autoimmune Disorders), By Region, And Segment Forecasts, 2018 - 2025
出版日期: 2018年07月17日内容资讯: 英文 70 Pages
简介

全球生物相似药市场,预计从2018年到2025年以34.2%的年复合成长率发展,成长到2025年614亿7,000万美元规模的市场。由于许多主要生物医药品的专利即将届满,许多企业致力于生物相似药的开发。

本报告提供全球生物相似药市场调查,市场概要,各产品、应用领域、地区的市场规模的变化与预测,市场趋势,市场占有率,成长要素及阻碍因素分析,市场机会,竞争情形,主要企业的简介等全面性资讯。

目录

第1章 调查方法

第2章 摘要整理

  • 市场概要

第3章 市场变数、趋势、范围

  • 市场区隔和范围
  • 成长要素与分析
  • 阻碍因素与分析
  • 市场机会
  • SWOT分析
  • 波特的五力分析
  • 竞争情形:市场定位分析

第4章 全球生物相似药市场分析与预测:各产品

  • 市场趋势分析:各产品
  • 重组非糖基化蛋白质
    • 人体生长荷尔蒙
    • 颗粒细胞增生因子
    • 干扰素
    • 胰岛素
  • 重组糖基化蛋白质
    • 促血红细胞生长素
    • 单株抗体
    • 促滤泡素

第5章 全球生物相似药市场分析与预测:各应用领域

  • 市场趋势分析:各应用领域
  • 肿瘤
  • 血液疾病
  • 生长激素缺乏症
  • 慢性疾病、自体免疫疾病
  • 其他

第6章 全球生物相似药市场分析与预测:各地区

  • 市场占有率:各地区
  • 北美
  • 欧洲
  • 亚太地区
  • 其他地区

第7章 竞争情形

  • 企业简介
    • Amgen Inc.
    • F Hoffmann-La Roche Ltd
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Samsung Bioepis
    • Biocon
    • Mylan N.V.
    • Celltrion Healthcare
    • AbbVie Inc

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 978-1-68038-916-6

The global biosimilars market size is expected to reach a value of USD 61.47 billion by 2025, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 34.2% over the forecast period. Major biological drugs are approaching the patent cliff. This is the most significant driving factor for the market. For instance, Roche's MabThera/Rituxan (rituximab), a monoclonal antibody biologics was approved by the U.S. Food and Drug Administration (FDA) in November 1997 and its U.S. patent expired in September 2016. Several companies such as Amgen, Boehringer Ingelheim, and Pfizer are focusing on development of biosimilar drug of rituximab.

Furthermore, lower cost of biosimilars compared to patented biologics and positive outcomes in clinical trials are expected to boost market growth. For instance, in July 2016; Allergan plc and Amgen stated results from a Phase 3 clinical study of ABP 980 compared with trastuzumab, a recombinant DNA-derived humanized monoclonal antibody. This drug was approved for early and metastatic breast cancer and metastatic gastric cancer in many regions. Currently, there is a boom in pharmaceutical industry for the development of biosimilar drugs, which is a cost-saving alternative to biologic drugs. Amgen Inc.; Sandoz International GmbH; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Biocon; Samsung Bioepis; and Mylan N.V are some of the companies focusing on the development and production of biosimilars.

Further key findings from the report suggest:

  • In 2016, recombinant non-glycosylated protein was the largest revenue-grossing segment in the biosimilars market owing to prevalence of growth hormone deficiency and diabetes and other chronic diseases
  • Recombinant glycosylated protein segment is expected to grow at significant rate during the forecast period owing to demand for erythropoietin and monoclonal antibodies for treatment of cancer and anemia
  • Oncology accounted for the largest share in application segment in 2016 due to increasing adoption of low cost biosimilar drugs for cancer treatment
  • Europe was the leading regional segment in terms of revenue share in 2016 owing to favorable regulatory policies
  • North America is expected to witness the highest CAGR during the forecast period owing to high prevalence of chronic diseases and rising number of drug approvals

Some of the major players are: Amgen Inc.; F. Hoffmann-La Roche Ltd.; Sandoz International GmbH; Dr. Reddy's Laboratories Ltd.; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Samsung Bioepis; Biocon; and Mylan N.V.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Country Wise Market: Base Estimates
  • 1.2 Global Market: CAGR Calculation
  • 1.3 Region Based Segment Share Calculation
  • 1.4 Research Scope & Assumptions
  • 1.5 List of Data Sources
    • 1.5.1 Data for primary interviews, by sources
    • 1.5.2 Data for primary interviews, by region

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Biosimilars Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Increasing emphasis on cutting down healthcare expenditures
    • 3.2.2 Cost effectiveness of biosimilar drugs
    • 3.2.3 Positive outcome in the ongoing clinical trials
    • 3.2.4 R&D investments are increasing
    • 3.2.5 Patent expiration of biologics to boost the biosimilars market
  • 3.3 Market Restraint Analysis
    • 3.3.1 High manufacturing complexities and costs
    • 3.3.2 Presence of non-original biologics and biobetters
  • 3.4 Key Opportunities Prioritized
    • 3.4.1 Key opportunities prioritized, by product
    • 3.4.2 Key opportunities prioritized, by application
  • 3.5 Biosimilars- SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.6 Industry Analysis - Porter's
  • 3.7 Competitive Landscape: Market Position Analysis, 2016

Chapter 4 Biosimilars Market: Product Estimates & Trend Analysis

  • 4.1 Biosimilars Market: Product Movement Analysis
  • 4.2 Recombinant Non-Glycosylated Proteins
    • 4.2.1 Recombinant non-glycosylated proteins market, 2014 - 2025 (USD Million)
    • 4.2.2 Human growth hormone
      • 4.2.2.1 Human growth hormone market, 2014 - 2025 (USD Million)
    • 4.2.3 Granulocyte colony-stimulating factor
      • 4.2.3.1 Granulocyte colony-stimulating factor market, 2014 - 2025 (USD Million)
    • 4.2.4 Interferons
      • 4.2.4.1 Interferons market, 2014 - 2025 (USD Million)
    • 4.2.5 Insulin
      • 4.2.5.1 Insulin market, 2014 - 2025 (USD Million)
  • 4.3 Recombinant Glycosylated Proteins
    • 4.3.1 Recombinant glycosylated proteins market, 2014 - 2025 (USD Million)
    • 4.3.2 Erythropoietin
      • 4.3.2.1 Erythropoietin market, 2014 - 2025 (USD Million)
    • 4.3.3 Monoclonal antibodies
      • 4.3.3.1 Monoclonal antibodies market, 2014 - 2025 (USD Million)
    • 4.3.4 Follitropin
      • 4.3.4.1 Follitropin market, 2014 - 2025 (USD Million)

Chapter 5 Biosimilars Market: Application Estimates & Trend Analysis

  • 5.1 Biosimilars Market: Application Movement Analysis
  • 5.2 Oncology
    • 5.2.1 Oncology market, 2014 - 2025 (USD Million)
  • 5.3 Blood Disorders
    • 5.3.1 Blood disorders market, 2014 - 2025 (USD Million)
  • 5.4 Growth Hormonal Deficiency
    • 5.4.1 Growth hormonal deficiency market, 2014 - 2025 (USD Million)
  • 5.5 Chronic and Autoimmune Disorders
    • 5.5.1 Chronic and autoimmune disorders market, 2014 - 2025 (USD Million)
  • 5.6 Others
    • 5.6.1 Others market, 2014 - 2025 (USD Million)

Chapter 6 Biosimilars Market: Regional Estimates & Trend Analysis, by Product and Application

  • 6.1 Biosimilars Market Share by Region, 2016 & 2025
  • 6.2 North America
    • 6.2.1 U.S.
      • 6.2.1.1 U.S. biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.2.1.2 U.S. biosimilars market, by application, 2014 - 2025 (USD Million)
    • 6.2.2 Canada
      • 6.2.2.1 Canada biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.2.2.2 Canada biosimilars market, by application, 2014 - 2025 (USD Million)
  • 6.3 Europe
    • 6.3.1 Germany
      • 6.3.1.1 Germany biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.3.1.2 Germany biosimilars market, by application, 2014 - 2025 (USD Million)
    • 6.3.2 U.K.
      • 6.3.2.1 U.K. biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.3.2.2 U.K. biosimilars market, by application, 2014 - 2025 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 China
      • 6.4.1.1 China biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.4.1.2 China biosimilars market, by application, 2014 - 2025 (USD Million)
    • 6.4.2 India
      • 6.4.2.1 India biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.4.2.2 India biosimilars market, by application, 2014 - 2025 (USD Million)
  • 6.5 ROW

Chapter 7 Competitive Landscape

  • 7.1 Company Profiles
    • 7.1.1 Amgen Inc.
      • 7.1.1.1 Company overview
      • 7.1.1.2 Financial performance
      • 7.1.1.3 Product benchmarking
      • 7.1.1.4 Strategic initiatives
    • 7.1.2 F Hoffmann-La Roche Ltd
      • 7.1.2.1 Company overview
      • 7.1.2.2 Financial performance
      • 7.1.2.3 Product benchmarking
      • 7.1.2.4 Strategic initiatives
    • 7.1.3 Sandoz International GmbH
      • 7.1.3.1 Company overview
      • 7.1.3.2 Financial performance
      • 7.1.3.3 Product benchmarking
      • 7.1.3.4 Strategic initiatives
    • 7.1.4 Dr. Reddy's Laboratories Ltd.
      • 7.1.4.1 Company overview
      • 7.1.4.2 Financial performance
      • 7.1.4.3 Product benchmarking
      • 7.1.4.4 Strategic initiatives
    • 7.1.5 Teva Pharmaceutical Industries Ltd.
      • 7.1.5.1 Company overview
      • 7.1.5.2 Financial performance
      • 7.1.5.3 Product benchmarking
      • 7.1.5.4 Strategic initiatives
    • 7.1.6 Pfizer Inc.
      • 7.1.6.1 Company overview
      • 7.1.6.2 Financial performance
      • 7.1.6.3 Product benchmarking
      • 7.1.6.4 Strategic initiatives
    • 7.1.7 Samsung Bioepis
      • 7.1.7.1 Company overview
      • 7.1.7.2 Financial performance
      • 7.1.7.3 Product benchmarking
      • 7.1.7.4 Strategic initiatives
    • 7.1.8 Biocon
      • 7.1.8.1 Company overview
      • 7.1.8.2 Financial performance
      • 7.1.8.3 Product benchmarking
      • 7.1.8.4 Strategic initiatives
    • 7.1.9 Mylan N.V.
      • 7.1.9.1 Company overview
      • 7.1.9.2 Financial performance
      • 7.1.9.3 Product benchmarking
      • 7.1.9.4 Strategic initiatives
    • 7.1.10 Celltrion Healthcare
      • 7.1.10.1 Company overview
      • 7.1.10.2 Financial performance
      • 7.1.10.3 Product benchmarking
      • 7.1.10.4 Strategic initiatives
    • 7.1.11 AbbVie Inc.
      • 7.1.11.1 Company overview
      • 7.1.11.2 Financial performance
      • 7.1.11.3 Product benchmarking
      • 7.1.11.4 Strategic initiatives

List of Tables

  • TABLE 1 Factors used in segment share estimation
  • TABLE 2 List of secondary data sources
  • TABLE 3 Primary interview details, by source
  • TABLE 4 Primary interview details, by region
  • TABLE 5 North America biosimilars market, by country, 2014 - 2025 (USD Million)
  • TABLE 6 North America biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 7 North America biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 8 North America biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 9 North America biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 10 U.S. biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 11 U.S. biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 12 U.S. biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 13 U.S. biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 14 Canada biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 15 Canada biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 16 Canada biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 17 Canada biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 18 Europe biosimilars market, by country, 2014 - 2025 (USD Million)
  • TABLE 19 Europe biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 20 Europe biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 21 Europe biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 22 Europe biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 23 Germany biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 24 Germany biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 25 Germany biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 26 Germany biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 27 U.K. biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 28 U.K. biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 29 U.K. biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 30 U.K. biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 31 Asia Pacific biosimilars market, by country, 2014 - 2025 (USD Million)
  • TABLE 32 Asia Pacific biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 33 Asia Pacific biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 34 Asia Pacific biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 35 Asia Pacific biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 36 China biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 37 China biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 38 China biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 39 China biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 40 India biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 41 India biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 42 India biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 43 India biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 44 ROW biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 45 ROW biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 46 ROW biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 47 ROW biosimilars market, by application, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Primary interviews, by sources
  • FIG. 2 Primary interviews, by region
  • FIG. 3 Market summary
  • FIG. 4 Market trends & outlook
  • FIG. 5 Market segmentation & scope
  • FIG. 6 Market driver relevance analysis (Current & future impact)
  • FIG. 7 Key opportunities prioritized, by product
  • FIG. 8 Key opportunities prioritized, by application
  • FIG. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • FIG. 10 Porter's five forces analysis
  • FIG. 11 Market position analysis, 2016
  • FIG. 12 Biosimilars market product outlook: Key takeaways
  • FIG. 13 Biosimilars market: Product movement analysis
  • FIG. 14 Recombinant non-glycosylated proteins market, 2014 - 2025 (USD Million)
  • FIG. 15 Human growth hormone market, 2014 - 2025 (USD Million)
  • FIG. 16 Granulocyte colony-stimulating factor market, 2014 - 2025 (USD Million)
  • FIG. 17 Interferons market, 2014 - 2025 (USD Million)
  • FIG. 18 Insulin market, 2014 - 2025 (USD Million)
  • FIG. 19 Recombinant glycosylated proteins market, 2014 - 2025 (USD Million)
  • FIG. 20 Erythropoietin market, 2014 - 2025 (USD Million)
  • FIG. 21 Monoclonal antibodies market, 2014 - 2025 (USD Million)
  • FIG. 22 Follitropin market, 2014 - 2025 (USD Million)
  • FIG. 23 Biosimilars market application outlook: Key takeaways
  • FIG. 24 Biosimilars market: Application movement analysis
  • FIG. 25 Oncology market, 2014 - 2025 (USD Million)
  • FIG. 26 Blood disorders market, 2014 - 2025 (USD Million)
  • FIG. 27 Growth hormonal deficiency market, 2014 - 2025 (USD Million)
  • FIG. 28 Chronic and autoimmune disorders market, 2014 - 2025 (USD Million)
  • FIG. 29 Others market, 2014 - 2025 (USD Million)
  • FIG. 30 Regional market place: Key takeaways
  • FIG. 31 Regional outlook, 2016 & 2025
Back to Top